FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287						
Estimated average burden							
hours nor response.	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Mulroy Robert J.				2. Issuer Name <b>and</b> Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
			1	MAC	ck ]					_  :	X Director	Director		Owner	
(Last)	(F	First)	(Middle)								:	Officer below)	(give title	Other below	(specify
C/O MERRIMACK PHARMACEUTICALS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 02/08/2016					President and CEO						
ONE KENDALL SQUARE, SUITE B7201				L											
(Street)			—   4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Individual or Joint/Group Filing (Check Applicable Line)					
CAMBR	IDGE N	ſΑ	02139										•	Reporting Pers	
												Form fi Person	ed by More	than One Rep	orting
(City)	(5	State)	(Zip)												
		Ta	ble I - Non-D	erivati	ve Se	ecurities	s Ac	quired, D	isposed (	of, or Be	neficiall	y Owned			
1. Title of Security (Instr. 3)  2. Transa Date (Month/D				Execution Date,		Code (Instr.		ed (A) or etr. 3, 4 and	5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code V	Amount	(A) o (D)	r Price	Transaction(s) (Instr. 3 and 4)			(111511.4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	xercise (Month/Day/Year) if any e of vative (Month/Day/Y		Code (Instr.		Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownersh Form: y Direct (D or Indirec (I) (Instr.	Beneficial Ownership t (Instr. 4)
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(5)	
Stock Option (right to buy)	\$5.42	02/08/2016		A		250,000		(1)	02/07/2026	Common Stock	250,000	\$0.00	250,000	) D	

## Explanation of Responses:

1. This option vests as to 1/12th of the total number of shares on 5/8/16 and an additional 1/12th of the total number of shares at the end of each successive three month period thereafter until 2/8/19.

## Remarks:

/s/ Jeffrey A. Munsie, attorney-

02/10/2016

in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.